Pancreatic endocrine tumors

Pathology Case Reviews

Volumn 11, Issue 6, 2006, Pages 256-267

  Klöppel, Günter ^a   Anlauf, Martin ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Classification; Endocrine tumors; Histopathology; Molecular genetics; Pancreas; Prognosis

Indexed keywords

SOMATOSTATIN RECEPTOR;

ASPIRATION CYTOLOGY; ELECTRON MICROSCOPY; ENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; PANCREAS TUMOR; PANCREATIC ENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

EID: 33845465408     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/01.pcr.0000251146.82702.2d     Document Type: Review

References (184)

1. Heitz PU, Komminoth P, Perren A, et al. Pancreatic endocrine tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics: Tumours of Endocrine Organs: WHO Classification of Tumors. Lyon: IARC Press; 2004:177-182.
2. Klöppel G, Willemer S, Stamm B, et al. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I: an immunocytochemical study of nine patients. Cancer. 1986;57:1824-1832.
3. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30:560-574.
4. Lohmann DR, Funk A, Niedermeyer HP, et al. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch [B] Cell Pathol. 1993;64:293-296.
5. Komminoth P, Roth J, Muletta-Feurer S, et al. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 1996;81:2041-2046.
6. Lollgen RM, Hessman O, Szabo E, et al. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer. 2001;92:812-815.
7. Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer. 2001;84:253-262.
8. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J. 2001;7:251-258.
9. Serrano J, Goebel SU, Peghini PL, et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab. 2000;85:4146-4156.
10. Probst A, Lotz M, Heitz PU. Von Hippel-Lindau's disease, syringomyelia and multiple endocrine tumors: a complex neuroendocrinopathy. Virchows Arch [A] Pathol Anat. 1978;378:265-272.
11. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev. 2005;26:615-661.
12. Larsson C, Skogseid B, Öberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332:85-87.
13. Gortz B, Roth J, Krahenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol. 1999;154:429-436.
14. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Res. 2001;61:5186-5192.
15. Zhao J, Moch H, Scheidweiler AF, et al. Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer. 2001;32:364-372.
16. Speel EJ, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol. 1999;155:1787-1794.
17. Stumpf E, Aalto Y, Hoog A, et al. Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer. 2000;29:83-87.
18. Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25. 3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. J Pathol. 2001;194:451-458.
19. Barghorn A, Speel EJ, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol. 2001;158:1903-1911.
20. Solcia E, Capella C, Klöppel G. Tumors of the Pancreas: AFIP Atlas of Tumor Pathology, Third Series, Fascicle 20. Washington, DC: Armed Forces Institute of Pathology; 1997.
21. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract. 1988;183:155-168.
22. Kent RB 3, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumours. Ann Surg. 1981;193:185-190.
23. Broughan TA, Leslie JD, Soto JM, et al. Pancreatic islet cell tumors. Surgery. 1986;99:671-678.
24. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677-686.
25. Service FJ, McMahon MM, O'Brien PC, et al. Functioning insulinoma: incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711-719.
26. Donow C, Pipeleers-Marichal M, Stamm B, et al. Pathologie des Insulinoms und Gastrinoms: Lokalisation, Gröe, Multizentrizität, Assoziation mit der multiplen endokrinen Neoplasie Typ I und Malignität. Dtsch Med Wochenschr. 1990;115:1386-1391.
27. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas: analysis of autopsy cases. Dig Dis Sci. 1991;36:933-942.
28. Donow C, Pipeleers-Marichal M, Schröder S, et al. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991;68:1329-1334.
29. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637-1649.
30. Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN 1 pancreas: a histological and immunohistochemical study. World J Surg. 1984;8:561-574.
31. Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322:723-727.
32. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol. 2004;15:275-292.
33. Reubi JC, Häcki WH, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab. 1987;65:1127-1134.
34. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab. 1990;71:566-574.
35. Kulaksiz H, Eissele R, Rössler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52-60.
36. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
37. Davtyan H, Nieberg R, Reber HA. Pancreatic cystic endocrine neoplasms. Pancreas. 1990;5:230-233.
38. Prescott RJ, Manson J, Haboubi NY. Malignant islet cell tumour arising in chronic pancreatitis. Histopathology. 1993;22:499-501.
39. Tomita T, Bhatia P, Gourley W. Mucin producing islet cell adenoma. Hum Pathol. 1981;12:850-853.
40. Guarda LA, Silva EG, Ordóñez NG, et al. Clear cell islet cell tumor. Am J Clin Pathol. 1983;79:512-517.
41. Radi MJ, Fenoglio-Preiser CM, Chiffelle T. Functioning oncocytic islet-cell carcinoma: report of a case with electron-microscopic and immunohistochemical confirmation. Am J Surg Pathol. 1985;9:517-524.
42. Gotchall J, Traweek ST, Stenzel P. Benign oncocytic endocrine tumor of the pancreas in a patient with polyarteritis nodosa. Hum Pathol. 1987;18:967-969.
43. Ordóñez NG, Silva EG. Islet cell tumour with vacuolated lipid-rich cytoplasm: a new histological variant of islet cell tumour. Histopathology. 1997;31:157-160.
44. van Eeden S, de Leng WWJ, Offerhaus GJA, et al. Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules. Am J Surg Pathol. 2004;28:813-820.
45. Kapran Y, Bauersfeld J, Anlauf M, et al. Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch. 2006;448:394-398.
46. Dayal Y, Doos WG, O'Brien MJ, et al. Psammomatous somatostatinomas of the duodenum. Am J Surg Pathol. 1983;7:653-665.
47. Taccagni GL, Carlucci M, Sironi M, et al. Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultrastructural study. Am J Gastroenterol. 1986;81:33-37.
48. Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol. 1998;153:223-231.
49. Hoang MP, Hruban RH, Albores-Saavedra J. Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol. 2001;25:602-609.
50. Oertel JE, Heffess CS, Oertel YC. Pancreas Diagn Surg Pathol. 1989;2:1057-1093.
51. Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol. 2003;14:293-301.
52. Gould VE, Wiedenmann B, Lee I, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol. 1987;126:243-257.
53. Hagn C, Schmid KW, Fischer-Colbrie R, et al. Chromogranin A, B and C in human adrenal medulla and endocrine tissues. Lab Invest. 1986;55:405-411.
54. Lloyd RV, Mervak T, Schmidt K, et al. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol. 1984;8:607-614.
55. Krisch K, Horvat G, Krisch I, et al. Immunochemical characterization of a novel secretory protein (defined by monoclonal antibody HISL-19) of peptide hormone producing cells which is distinct from chromogranin A, B, and C. Lab Invest. 1988;58:411-420.
56. Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978;276:834-836.
57. Lloyd RV, Jin L, Qian X, et al. Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries. Am J Pathol. 1995;146:1188-1198.
58. Tischler AS, Mobtaker H, Mann K, et al. Anti-lymphocyte antibody Leu-7 (HNK-1) recognizes a constituent of neuroendocrine granule matrix. J Histochem Cytochem. 1986;34:1213-1216.
59. Jin L, Hemperly JJ, Lloyd RV. Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. Am J Pathol. 1991;138:961-969.
60. Schmitt-Gräff A, Müller H, Rancso C, et al. Molecules of regulated secretion are differentiation markers of neuroendocrine tumors [in German]. Verh Dtsch Ges Pathol. 1997;81:157-161.
61. Bordi C, Pilato FP, D'Adda T. Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours. Virchows Arch [A] Pathol Anat. 1988;413:387-398.
62. Schmidt WE, Siegel EG, Lamberts R, et al. Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues. Endocrinology. 1988;123:1395-1404.
63. Höfler H, Denk H, Lackinger E, et al. Immunocytochemical demonstration of intermediate filament cytoskeleton proteins in human endocrine tissues and (neuro-) endocrine tumours. Virchows Arch [A] Pathol Anat. 1986;409:609-626.
64. Hoorens A, Prenzel K, Lemoine NR, et al. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol. 1998;185:53-60.
65. Perez MA, Saul SH, Trojanowski JQ. Neurofilament and chromogranin expression in normal and neoplastic neuroendocrine cells of the human gastrointestinal tract and pancreas. Cancer. 1990;65:1219-1227.
66. Heitz PU, Kasper M, Polak JM, et al. Pancreatic endocrine tumours: immunohistochemical analysis of 125 tumours. Hum Pathol. 1982;13:263-271.
67. Höfler H, Ruhri C, Pütz B, et al. Oncogene expression in endocrine pancreatic tumors. Virchows Arch [B] Cell Pathol. 1988;55:355-361.
68. McKenzie KJ, Hind C, Farquharson MA, et al. Demonstration of insulin production and storage in insulinomas by in situ hybridization and immunocytochemistry. J Pathol. 1997;181:218-222.
69. Larsson LI, Grimelius L, Håkanson R, et al. Mixed endocrine pancreatic tumors producing several peptide hormones. Am J Pathol. 1975;79:271-284.
70. Mukai K, Grotting JC, Greider MH, et al. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol. 1982;6:387-399.
71. Tomita T, Friesen SR, Kimmel JR, et al. Pancreatic polypeptide-secreting islet cell tumors: a study of three cases. Am J Pathol. 1983;113:134-142.
72. Heitz P, Polak JM, Bloom SR, et al. Cellular origin of human pancreatic polypeptide (HPP) in endocrine tumours of the pancreas. Virchows Arch [B] Cell Pathol. 1976;21:259-265.
73. Capella C, La Rosa S, Solcia E. Criteria for malignancy in pancreatic endocrine tumors. Endocr Pathol. 1997;8:87-90.
74. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323-333.
75. Pelosi G, Pasini F, Bresaola E, et al. High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine tumours. J Pathol. 1997;183:62-69.
76. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27:1124-1134.
77. Clarke MR, Baker EE, Weyant RJ, et al. Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocr Pathol. 1997;8:181-187.
78. Pelosi G, Zamboni G, Doglioni C, et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol. 1992;16:1215-1225.
79. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol. 2004;28:1145-1153.
80. Klöppel G, Höfler H, Heitz PU. Pancreatic endocrine tumours in man. In: Polak JM, ed. Diagnostic Histopathology of Neuroendocrine Tumours. Edinburgh: Churchill Livingstone; 1993:91-121.
81. Rüschoff J, Willemer S, Brunzel M, et al. Nucleolar organizer regions and glycoprotein-hormone alpha-chain reaction as markers of malignancy in endocrine tumours of the pancreas. Histopathology. 1993;22:51-57.
82. Viale G, Doglioni C, Gambacorta M, et al. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70:2268-2277.
83. Heitz PU, Kasper M, Klöppel G, et al. Glycoprotein-hormone alphachain production by pancreatic endocrine tumors: a specific marker for malignancy: immunocytochemical analysis of tumors of 155 patients. Cancer. 1983;51:277-282.
84. Perren A, Komminoth P, Heitz PU. Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci. 2004;1014:199-208.
85. Field JB. Insulinoma. In: Mazzaferri EL, Samaan NA, eds. Endocrine Tumors. Boston: Blackwell Scientific Publications; 1993:497-530.
86. Heik SCW, Klöppel G, Krone W, et al. Hypoglykämie durch Insulinom bei Diabetes mellitus. Dtsch Med Wochenschr. 1988;113:1714-1717.
87. Mann JR, Rayner PH, Gourevitch A. Insulinoma in childhood. Arch Dis Child. 1969;44:435-442.
88. Lo CY, Lam KY, Kung AW, et al. Pancreatic insulinomas: a 15-year experience. Arch Surg. 1997;132:926-930.
89. Fournet JC, Junien C. Genetics of congenital hyperinsulinism. Endocr Pathol. 2004;15:233-240.
90. Sempoux C, Guiot Y, Dahan K, et al. The focal form of persistent hyperinsulinemic hypoglycemia of infancy: morphological and molecular studies show structural and functional differences with insulinoma. Diabetes. 2003;52:784-794.
91. Goossens A, Gepts W, Saudubray JM, et al. Diffuse and focal nesidioblastosis: a clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol. 1989;13:766-775.
92. de Lonlay P, Fournet JC, Touati G, et al. Heterogeneity of persistent hyperinsulinaemic hypoglycaemia: a series of 175 cases. Eur J Pediatr. 2002;161:37-48.
93. Reinecke-Lüthge A, Koschoreck F, Klöppel G. The molecular basis of persistent hyperinsulinemic hypoglycemia of infancy and its pathologic substrates. Virchows Arch. 2000;436:1-5.
94. Keller A, Stone AM, Valderrama E, et al. Pancreatic nesidioblastosis in adults: report of a patient with hyperinsulinemic hypoglycemia. Am J Surg. 1983;145:412-416.
95. Gould VE, Chejfec G, Shah K, et al. Adult nesidiodysplasia. Semin Diagn Pathol. 1984;1:43-53.
96. Weinstock G, Margulies P, Kahn E, et al. Islet cell hyperplasia: an unusual cause of hypoglycemia in an adult. Metabolism. 1986;35:110-117.
97. Albers N, Löhr M, Bogner U, et al. Nesidioblastosis of the pancreas in an adult with persistent hyperinsulinemic hypoglycemia. Am J Clin Pathol. 1989;91:336-340.
98. Anlauf M, Wieben D, Perren A, et al. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence and characterization of β-cell changes. Am J Surg Pathol. 2005;29:524-533.
99. Stefanini P, Carboni M, Patrassi N, et al. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery. 1974;75:597-609.
100. Miyazaki K, Funakoshi A, Nishihara S, et al. Aberrant insulinoma in the duodenum. Gastroenterology. 1986;90:1280-1285.
101. Adamson AR, Grahame-Smith DG, Bogomoletz V, et al. Malignant argentaffinoma with carcinoid syndrome and hypoglycaemia. BMJ. 1971;3:93-94.
102. Pelletier G, Cortot A, Launay JM, et al. Serotonin-secreting and insulin-secreting ileal carcinoid tumor and the use of in vitro culture of tumoral cells. Cancer. 1984;54:319-322.
103. Shames JM, Dhurandhar NR, Blackard WG. Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med. 1968;44:632-637.
104. Kiang DT, Bauer GE, Kennedy BJ. Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia. Cancer. 1973;31:801-805.
105. Ashton MA. Strumal carcinoid of the ovary associated with hyperinsulinaemic hypoglycaemia and cutaneous melanosis. Histopathology. 1995;27:463-467.
106. Liu TH, Tseng HC, Zhu Y, et al. Insulinoma: an immunohistochemical and morphologic analysis of 95 cases. Cancer. 1985;56:1420-1429.
107. Westermark P, Engström U, Johnson KH, et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A. 1990;87:5036-5040.
108. Rindi G, Terenghi G, Westermark G, et al. Islet amyloid polypeptide in proliferating pancreatic B cells during development, hyperplasia, and neoplasia in humans and mice. Am J Pathol. 1991;138:1321-1334.
109. Westermark P, Grimelius L, Polak JM, et al. Amyloid in polypeptide hormone-producing tumors. Lab Invest. 1977;37:212-215.
110. Stridsberg M, Berne C, Sandler S, et al. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule. Diabetologia. 1993;36:843-849.
111. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, et al, eds. The Pancreas: Biology, Pathobiology and Disease. 2nd ed. New York: Raven Press; 1993:931-978.
112. Zollinger RM. Gastrinoma: the Zollinger-Ellison syndrome. Semin Oncol. 1987;14:247-252.
113. Ruszniewski P, Podevin P, Cadiot G, et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas. 1993;8:295-304.
114. Mehring UM, Jäger HJ, Klöppel G, et al. Pankreatischer Polypeptidsezernierender endokriner Pankreastumor assoziiert mit multiplen Ulcera ventriculi et duodeni. Langenbecks Arch Chir. 1997;382:134-137.
115. Chey WY, Chang TM, Lee KY, et al. Ulcerogenic tumor syndrome of the pancreas associated with a nongastrin acid secretagogue. Ann Surg. 1989;210:139-149.
116. Anlauf M, Perren A, Meyer CL, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128:1187-1198.
117. Vella MA, Cowie AG, Gorsuch AN, et al. Giant gastrinoma in a patient with multiple endocrine adenopathy (type 1). J R Soc Med. 1988;81:359-360.
118. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic and hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006. In press.
119. Klöppel G, Clemens A. The biological relevance of gastric neuroendocrine tumors. Yale J Biol Med. 1996;69:69-74.
120. Solcia E, Capella C, Buffa R, et al. Pathology of the Zollinger-Ellison syndrome. In: Fenoglio LM, Wolf M, eds. Progress in Surgical Pathology, Vol. 1. New York: Masson; 1980:119-133.
121. Antonioli DA, Dayal Y, Dvorak AM, et al. Zollinger-Ellison syndrome: cure by surgical resection of a jejunal gastrinoma containing growth hormone releasing factor. Gastroenterology. 1987;92:814-823.
122. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. Am J Surg. 1984;147:25-31.
123. Nord KS, Joshi V, Hanna M, et al. Zollinger-Ellison syndrome associated with a renal gastrinoma in a child. J Pediatr Gastroenterol Nutr. 1986;5:980-986.
124. Margolis RM, Jang N. Zollinger-Ellison syndrome associated with pancreatic cystadenocarcinoma. N Engl J Med. 1984;311:1380-1381.
125. Morgan DR, Wells M, MacDonald RC, et al. Zollinger-Ellison syndrome due to a gastrin secreting ovarian mucinous cystadenoma: case report. Br J Obstet Gynaecol. 1985;92:867-869.
126. Pipeleers-Marichal M, Donow C, Heitz PU, et al. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg. 1993;17:481-488.
127. Stabile BE, Passaro E Jr. Benign and malignant gastrinoma. Am J Surg. 1985;149:144-150.
128. Delcore R Jr, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann Surg. 1988;208:291-298.
129. Thompson JC, Lewis BG, Wiener I, et al. The role of surgery in the Zollinger-Ellison syndrome. Ann Surg. 1983;197:594-607.
130. Bordi C, Costa A, Missale G. ECL cell proliferation and gastrin levels. Gastroenterology. 1975;68:205-206.
131. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185-200.
132. D'Adda T, Corleto V, Pilato FP, et al. Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome: correspondence with light microscopic findings. Gastroenterology. 1990;99:17-26.
133. Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia: a newly recognized association. Am J Surg Pathol. 1990;14:503-513.
134. Mallinson CN, Bloom SR, Warin AP, et al. A glucagonoma syndrome. Lancet. 1974;ii:1-5.
135. Fujita J, Seino Y, Ishida H, et al. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Cancer. 1986;57:860-865.
136. Ruttman E, Klöppel G, Bommer G, et al. Pancreatic glucagonoma with and without syndrome: immunocytochemical study of 5 tumour cases and review of the literature. Virchows Arch [A] Pathol Anat. 1980;388:51-67.
137. Bordi C, Ravazzola M, Baetens D, et al. A study of glucagonomas by light and electron microscopy and immunofluorescence. Diabetes. 1979;28:925-936.
138. Hamid QA, Bishop AE, Sikri KL, et al. Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology. 1986;10:119-133.
139. Bloom SR, Polak JM, Pearse AGE. Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet. 1973;ii:14-16.
140. Trump DL, Livingston JN, Baylin SB. Watery diarrhea syndrome in an adult with ganglioneuroma-pheochromocytoma: identification of vasoactive intestinal peptide, calcitonin, and catecholamines and assessment of their biologic activity. Cancer. 1977;40:1526-1532.
141. Mendelsohn G, Eggleston JC, Olson JL, et al. Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest. 1979;41:144-149.
142. Capella C, Polak JM, Buffa R, et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors: a histologic, histochemical, ultrastructural and biochemical study of 32 cases. Cancer. 1983;52:1860-1874.
143. Udall JN Jr. Diarrhea due to hormone-secreting tumours. In: Lebenthal E, ed. Textbook of Gastroenterology and Nutrition in Infancy. 2nd ed. New York: Raven; 1989:1193-1205.
144. Long RG, Bryant MG, Mitchell SJ, et al. Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). BMJ (Clin Res Ed). 1981;282:1767-1771.
145. Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea: report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med. 1974;133:492-499.
146. Tomita T, Kimmel JR, Friesen SR, et al. Pancreatic polypeptide cell hyperplasia with and without watery diarrhea syndrome. J Surg Oncol. 1980;14:11-20.
147. Ooi A, Kameya T, Tsumuraya M, et al. Pancreatic endocrine tumours associated with WDHA syndrome: an immunohistochemical and electron microscopic study. Virchows Arch [A] Pathol Anat. 1985;405:311-323.
148. Krejs GJ, Orci L, Conlon JM, et al. Somatostatinoma syndrome: biochemical, morphologic and clinical features. N Engl J Med. 1979;301:285-292.
149. Sessa F, Arcidiaco M, Valenti L, et al. Metastatic psammomatous somatostatinoma of the pancreas causing severe ketoacedotic diabetes cured by surgery. Endocr Pathol. 1997;8:327-333.
150. Burke AP, Federspiel BH, Sobin LH, et al. Carcinoids of the duodenum: a histologic and immunohistochemical study of 65 tumors. Am J Surg Pathol. 1989;13:828-837.
151. Stamm B, Hedinger CE, Saremaslani P. Duodenal and ampullary carcinoid tumors: a report of 12 cases with pathological characteristics, polypeptide content and relation to the MEN 1 syndrome and von Recklingshausen's disease (neurofibromatosis). Virchows Arch [A] Pathol Anat. 1986;408:475-489.
152. Capella C, Riva C, Rindi G, et al. Histopathology, hormone products, and clinicopathological profile of endocrine tumors of the upper small intestine: a study of 44 cases. Endocr Pathol. 1991;2:92-110.
153. Heitz PU, Klöppel G, Polak JM, et al. Ectopic hormone production by endocrine tumors: localization of hormones at the cellular level by immunocytochemistry. Cancer. 1981;48:2029-2037.
154. Melmed S, Yamashita S, Kovacs K, et al. Cushing's syndrome due to ectopic proopiomelanocortin gene expression by islet cell carcinoma of the pancreas. Cancer. 1987;59:772-778.
155. Wilander E, El-Salhy M, Willén T, et al. Immunocytochemistry and electron microscopy of an argentaffin endocrine tumor of the pancreas. Virchows Arch [A] Pathol Anat. 1981;392:263-269.
156. Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9:357-373.
157. Berger G, Trouillas J, Bloch B, et al. Multihormonal carcinoid tumor of the pancreas: secreting growth hormone-releasing factor as a cause of acromegaly. Cancer. 1984;54:2097-2108.
158. Bostwick DG, Quan R, Hoffman AR, et al. Growth-hormone-releasing factor immunoreactivity in human endocrine tumors. Am J Pathol. 1984;117:167-170.
159. Rasbach DA, Hammond JM. Pancreatic islet cell carcinoma with hypercalcemia: primary hyperparathyroidism or humoral hypercalcemia of malignancy. Am J Med. 1985;78:337-342.
160. Broadus AE, Mangin M, Ikeda K, et al. Humoral hypercalcemia of cancer: identification of a novel parathyroid hormone-like peptide. N Engl J Med. 1988;319:556-563.
161. Fleury A, Fléjou JF, Sauvanet A, et al. Calcitonin-secreting tumors of the pancreas: about six cases. Pancreas. 1998;16:545-550.
162. Cryer PE, Hill GJ 2nd. Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia: response to streptozotocin. Cancer. 1976;38:2217-2221.
163. Hammar S, Sale G. Multiple hormone producing islet cell carcinomas of the pancreas: a morphological and biochemical investigation. Hum Pathol. 1975;6:349-362.
164. Asa SL, Kovacs K, Killinger DW, et al. Pancreatic islet cell carcinoma producing gastrin, ACTH, alpha-endorphin, somatostatin and calcitonin. Am J Gastroenterol. 1980;74:30-35.
165. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med. 1986;315:1-5.
166. Sadoff L, Gordon J, Goldman S. Amelioration of hypoglycemia in a patient with malignant insulinoma during the development of the ectopic ACTH syndrome. Diabetes. 1975;24:600-603.
167. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319:605-607.
168. Gloor F, Pletscher A, Hardmeier T. Metastasierendes Inselzelladenom des Pankreas mit 5-Hydroxytryptamin- und Insulin-Produktion. Schweiz Med Wochenschr. 1964;94:1476-1480.
169. Appleyard TN, Losowsky MS. A pancreatic tumor with carcinoid syndrome and hypoglycemia. Postgrad Med J. 1970;46:159-171.
170. Ohneda A, Otsuki M, Fujiya H, et al. A malignant insulinoma transformed into a glucagonoma syndrome. Diabetes. 1979;28:962-969.
171. Eckhauser FE, Cheung PS, Vinik AI, et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery. 1986;100:978-988.
172. Feurle GE, Helmstaedter V, Tischbirek K, et al. A multihormonal tumor of the pancreas producing neurotensin. Dig Dis Sci. 1981;26:1125-1133.
173. Padberg B, Schröder S, Capella C, et al. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch. 1995;426:541-548.
174. Samaan NA, Ouais S, Ordóñez NG, et al. Multiple endocrine syndrome type I: clinical, laboratory findings, and management in five families. Cancer. 1989;64:741-752.
175. Rosai J, Higa E, Davie J. Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis: a previously unrecognized association. Cancer. 1972;29:1075-1083.
176. Duh QY, Hybarger CP, Geist R, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg. 1987;154:142-148.
177. Komminoth P, Heitz PU, Klöppel G. Multiple endocrine disorders. In: Stefaneanu L, Sasano T, Kovacs K, eds. Molecular and Cellular Endocrine Pathology. Philadelphia, PA: Chapman & Hall; 1998.
178. Le Bodic MF, Heymann MF, Lecomte M, et al. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type I. Am J Surg Pathol. 1996;20:1378-1384.
179. Warner TF, Block M, Hafez GR, et al. Glucagonomas: ultrastructure and immunohistochemistry. Cancer. 1983;51:1091-1096.
180. Stacpoole PW, Jaspan J, Kasselberg AG, et al. A familial glucagonoma syndrome: genetic, clinical and biochemical features. Am J Med. 1981;70:1017-1026.
181. Eusebi V, Capella C, Bondi A, et al. Endocrine-paracrine cells in pancreatic exocrine carcinomas. Histopathology. 1981;5:599-613.
182. Ohike N, Jürgensen A, Pipeleers-Marichal M, et al. Mixed ductalendocrine carcinomas of the pancreas and ductal adenocarcinomas with scattered endocrine cells: characterization of the endocrine cells. Virchows Arch. 2003;442:258-265.
183. Ohike N, Kosmahl M, Klöppel G. Mixed acinar-endocrine carcinoma of the pancreas: a clinicopathological study and comparison with acinar-cell carcinoma. Virchows Arch. 2004;445:231-235.
184. Volante M, Rindi G, Papotti M. The grey zone between pure (neuro) endocrine and non-(neuro)endocrine tumors: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 2006. In press.